glp-1 news today september 29 2025 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1 Weight-Loss Drug Demonstration Begins

Its FDA-approved for the treatment of obesity under the brand name Wegovy

Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Industry Leaders Sanofi Eli Lilly Novo Nordisk AstraZeneca Biocon *Disclaimer: Major Players sorted in no particular order Recent Industry Developments March 2023: Eli Lilly announced it would cut the price of its most commonly prescribed insulin products by 70 percent in response to mounting political pressure over the high cost of diabetes medication

Gentamicin-loaded thermosetting hydrogel and moldable composite scaffold: formulation study and biologic evaluation

In addition, patients with tophi are often at risk for uric acid-related kidney stones, since they may be over-producers of uric acid and have elevated 24-hour urinary uric acid